INSTITUTE OF CHEMICAL BIOLOGY
 
  Drug Discovery
  Molecular Analysis
  Organic and Organometallic Chemistry
  Medicinal Chemistry
  Synthetic Medicinal Chemistry and Chemical Biology
  Structural Biology & Chemistry
  Molecular Endocrinology
  Signal Mediated Gene Expression
  Molecular & Cellular Ageing
  Biomedical Applications
  Holistic Approaches in Health
  Chemical Carcinogenesis and Genetic Toxicology
  Metabolic Engineering-Bioinformatics
  Biotechnology
  Enzyme and Synthetic Biotechnology
  Biomimetics & Nanobiotechnology
  Conjugated Polymers for Healthcare, Bioelectronics and Bioimaging

Synthetic Medicinal Chemistry and Chemical Biology

 

The K.C. Prousis group is focused on activities combining the fields of Synthetic Medicinal Chemistry and Chemical Biology. The group aims to provide new therapeutic approaches against several lethal diseases with high socioeconomic impact including Cancer, Neurodegenerative Diseases and Parasitic Neglected Diseases. The activities of the group follow two major research lines:

  • Design and synthesis of biologically active, small organic molecules towards the identification of new lead compounds for the prevention and treatment of diseases of our interest.
  • Design and synthesis of new strategic NIR fluorescence ‘smart probes’, mainly based on a Cyanine – BODIPY platform, suitable for Optical Imaging and Biomedical applications related to Cancer and Neurodegenerative Diseases. The use of these ‘smart probes’ will support early diagnosis and therapy, in a non-invasive manner and will provide the opportunity of Theranostic applications.

Theranostics

Research Team

Kyriakos Prousis, Associate Researcher

 

Research funding

European

  • H2020-MSCA-ITN-2017, EuroNeurotrophin: ‘A European training network for the discovery of neurotrophins small molecule mimetics as potential therapeutic agents for neurodegeneration and neuroinflammation’.  

National

  • GSRT Infrastructures program, Bioimaging–GR: ‘A Greek Research Infrastructure for Visualizing and Monitoring Fundamental Biological Processes’

 

Current Collaborations

National 

Res. Director T. Calogeropoulou, IBMCB-NHRF
Res. Director D. Papahatjis, IBMCB-NHRF
Res. Director M. Koufaki, IBMCB-NHRF
Prof. V. Roussis, Pharmacy Department, University of Athens
Prof. A. Gravanis, Medical School, University of Crete 
Ass. Prof. E. Ioannou, Pharmacy Department, University of Athens
Ass.  Prof. Ioannis Charalampopoulos, Foundation for Research and Technology Hellas, Asoc. Prof. A. Detsi, Department of Chemical Engineering, National Technical University of Athens

International

​Prof. M.-P. Costi, Pharmacy Department, University of Modena and Reggio Emilia, Italy
Dr A. Cordeiro-da-Silva, Instituto de Biologia Molecular e Celular, Porto, Portugal
Prof. Dame Pamela Shaw, University of Sheffield, Sheffield Institute for Translational Neuroscience, United Kingdom
Prof. S. Mangani, University of Siena, Italy
Prof. Rebecca Wade, HITS gGmbH, Molecular and Cellular Modeling Group, Germany
Prof. Christophe Rochais, Université de Caen Normandie, France
​Dr.  Vasileia-Ismini Alexaki, Technische Universität Dresden, Faculty of Medicine, Germany
​Dr.  Marie-Ann Ewart, AvantiCell Science Ltd., United Kingdom
Ass. Prof. Ka Wan Li, Stichting VU, Department of Molecular and Cellular Neurobiology, The Netherlands

 

Collaborations with Companies

Novartis (Hellas) S.A.C.I., Greece
Accelopment AG, Switzerland

 

Publications in Peer Reviewed Scientific Journals

  • “Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform” C. B. Moraes, G. Witt, M. Kuzikov, B. Ellinger, T. Calogeropoulou, K. C. Prousis, S. Mangani, F. Di Pisa, G. Landi, L. D. Iacono, C. Pozzi, L. H. Freitas-Junior, B. S. Pascoalino, C. P. Bertolacini, B. Behrens, O. Keminer, J. Leu, M. Wolf, J. Reinshagen, A. Cordeiro-da-Silva, N. Santarem, A. Venturelli, S. Wrigley, D. Karunakaran, B. Kebede, I. Pöhner, W. Müller, J. Panecka-Hofman, R. C. Wade, M. Fenske, J. Clos, J. M. Alunda, M. Jesús Corral, E. Uliassi, M. L. Bolognesi, P. Linciano, A. Quotadamo, S. Ferrari, M. Santucci, C. Borsari, M.P. Costi, and S. Gul; SLAS Discov. 201924(3),346-361
  • “BNN27, a 17-Spiroepoxy Steroid Derivative, Interacts With and Activates p75 Neurotrophin Receptor, Rescuing Cerebellar Granule Neurons from Apoptosis” I. Pediaditakis, A. Kourgiantaki, K. C. Prousis, C. Potamitis, K. P. Xanthopoulos, M. Zervou, T. Calogeropoulou, I. Charalampopoulos, A. Gravanis; Front Pharmacol. 2016, 7, article 512, 1-14.
  • “Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor” K. Alevizopoulos, K. Dimas, N. Papadopoulou, E.-M. Schmidt, A. Tsapara, S. Alkahtani, S. Honisch, K. C. Prousis, S. Alarifi, T. Calogeropoulou, F. Lang, C. Stournaras; Ongotarget 2016, 7, 24415-24428.
  • “Identification of Novel Chemical Scaffolds Inhibiting Trypanothione Synthetase from Pathogenic Trypanosomatids” D. Benítez, A. Medeiros, L. Fiestas, E. A. P. Zenere, F. Maiwald, K. C. Prousis, M. Roussaki, T. Calogeropoulou, A. Detsi, T. Jaeger, J. Šarlauskas, L. P. Mašič, C. Kunick, G. R. Labadie, L. Flohé, M. A. Comini; PLOS Negl. Trop. Dis. 2016, 10(4): e0004617.
  •  “An efficient synthetic approach towards fully functionalized tetronic acids: the use of 1,3-dioxolane-2,4-diones as novel protected-activated synthons of a-hydroxy acids” K. C. Prousis, J. Markopoulos, V. Mckee, O. Igglessi-Markopoulou; Tetrahedron, 2015, 66, 8637-8648.
  • “Design and synthesis of 21-alkynylaryl pregnenolone derivatives and evaluation of their anticancer activity”G. Szalóki, A. Pantzou, K. C. Prousis, O. Mavrofrydi, P. Papazafiri, T. Calogeropoulou; Bioorg.  Med. Chem., 2014, 22, 6980-6988.
  • “A steroidal Na+/K+ ATpase inhibitor triggers pro-apoptotic signaling and induces apoptosis in prostate and lung tumor cells” S. Honisch, S. Alkahtani, K. Michalis, L. Guilai, A. Saud A., Al-V. Hamad, K. Dimas, A. Abdullah A., K. C. Prousis, Al-D. Bader, T. Calogeropoulou, K. Alevizopoulos, F. Lang, C. Stournaras; Anticancer Agents Med. Chem., 2014, 14, 1161-1168.
  • “Reactivity of 2-methyl-4H-3,1-benzoxazin-4-ones and 2-methyl-4H-pyrido[2,3-d][1,3]oxazin-4-one under Microwave Irradiation Conditions” K. C. Prousis, A. Tzani,  N. Avlonitis,  T. Calogeropoulou, A. Detsi; J. Het. Chem 2013, 50, 1313-1321.
  •  “Effect of alkylphospholipids on Candida albicans biofilm formation and maturation” T. V. M. Vila, K. Ishida, W. de Souza, K. C. Prousis, T. Calogeropoulou, S. Rozental; J. Antimicrob. Chemother. 2013, 68, 113-125.
  • “Three step solid-phase synthesis of functionalized tetronic acids using an activated carbonate linker” D. Matiadis, K. C. Prousis, O. Igglessi-Markopoulou; Synth. Commun., 2013, 43, 392-397.
  • “Synthesis and crystal structure characterization of zinc (II) tetronic acid complexes” K. C. Prousis, G. Athanasellis, V. Stefanou, D. Matiadis, E. Kokalari, O. Igglessi-Markopoulou, V. Mc Kee, J. Markopoulos; Bioinorg. Chem. Appl.,2010, Art. ID 651652, 7 pages doi:10.1155/2010/651652.
  • “Design and synthesis of new adamantyl-substituted antileishmanial ether phospholipids.” I. Papanastasiou, K. C. Prousis, K. Georgikopoulou, T. Pavlidis, E. Scoulica, N. Kolocouris, T. Calogeropoulou; Bioorg. Med. Chem. Lett., 2010, 20,5484-5487.
  • “Efficient Efficient construction of functionalized 5-Carboxymethyl Tetramic Acids using N-Ac-L-aspartic Anhydride as Chiral Building Block” K. C. Prousis, J. Markopoulos, V. Mckee, O. Igglessi-Markopoulou; Tetrahedron, 2010, 66, 3944-3950.
  • “Solid-Phase Synthesis of Optically Active Substituted 2-Aminofuranones Using an Activated Carbonate Linker” D. Matiadis, K. C. Prousis, O. Igglessi-Markopoulou; Molecules 2009, 14, 3914-3921.
  • “Design and Synthesis of Novel Quinolinone-3-aminocarboxamides and their α-Lipoic Acid Adducts as Antioxidant and Antiiflammatory Agents.” A. Detsi, D. Bouloumbasi, K. C. Prousis, M. Koufaki, G. Athanasellis, G. Melagraki, A. Afantitis, O. Igglessi-Markopoulou, C. Kontogiorgis, D. Hadjipavlou-Litina; J. Med. Chem. 2007, 50, 2450-2458.
  • “A novel synthetic approach to the thiotetronic ring system, the key intermediate for thiolactomycin analogues” S. Kikionis, K. C. Prousis, A. Detsi, O. Igglessi-Markopoulou; ARKIVOC 2006 (xii) 1-10.
  • “A Novel Traceless Solid Phase Approach to Functionalized Tetramic Acids and 2-Amino-4-pyrrolinones” K. C. Prousis, A. Detsi, O. Igglessi-Markopoulou ; Synlett 2005, 18, 2763-2766.
  • “Solid phase synthesis of substituted 2-aminopyrrolin-4-ones via the spontaneous postcleavage cyclization” A. Detsi, P. Emirtzoglou, K. Prousis, V. Skouridou, O. Igglessi-Markopoulou; Synlett 2004, 2, 353-355.
  • “A Novel Access to 2-Amino Furanones via Cyclization of   Functionalized γ-Hydroxy-α,β-butenoates Derived from N-Hydroxybenzotriazole Esters of α-Hydroxy Acids” G. Athanasellis, A. Detsi, K. Prousis, O. Igglessi-Markopoulou, J. Markopoulos. Synthesis 2003, 1, 2015-2022.

 

Patents 

  1. Bio-inspired activators of proteasome with antiageing activity. PCT/GR 2019/000018.
 
 

 

 

 

 
 

 

   
       

 

 

© National Hellenic Research Foundation (NHRF), 48 Vassileos Constantinou Ave., 11635 Athens, Greece, Tel. +302107273700, Fax. +302107246618